Morbilliform drug eruption

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

A classic morbilliform eruption consists of small macules and papules that become confluent symmetrically over trunk and proximal limbs. In darker skin, red may be subtle and the active process may appear violaceous, grey-brown or be recognised through texture, itch and warmth. Mucosa is spared and the patient is systemically well or only mildly affected.

Assessment is a severity screen and causality exercise. List every exposure with start, stop and dose dates, then compare known latency with rash onset. Examine all skin and mucosa with consent. Blood tests are not mandatory for a small typical eruption in a well patient, but FBC, liver, renal and inflammatory tests are appropriate when fever, facial oedema or systemic symptoms create concern.

Clinical decisions in Morbilliform drug eruption depend on trajectory and consequence. Re-examine evolving skin, repeat focused systemic assessment when the patient changes, and reconcile every result with morphology and timing; a normal early test cannot neutralise worsening pain, mucosal injury or organ dysfunction.

Key points

Typical lesions are symmetrical pink, red, violaceous or brown macules and small papules beginning on trunk, often with itch and no mucosal erosion.
An uncomplicated eruption usually appears days after starting a medicine, but latency shortens after previous sensitisation and varies with the culprit.
Create a complete timeline including prescriptions, over-the-counter products, contrast, vaccines and intermittent medicines started or stopped in the preceding weeks.
Examine face, mouth, eyes, genital mucosa, skin tenderness, blistering, pustules, purpura, nodes and physiology before calling the eruption benign.
Stop the suspected medicine when clinically safe after discussing essential treatment alternatives; do not abruptly withdraw a vital medicine without a replacement plan.
Record drug, formulation, indication, dates, latency, morphology, severity and certainty rather than entering rash alone.
Morbilliform drug eruption must be assessed by lesion duration, onset, distribution, symptoms, mucosal findings, systemic physiology and the full medicine timeline rather than by colour alone.
For Morbilliform drug eruption, document the working diagnosis, excluded emergencies, uncertain culprit or trigger, treatment response and the exact safety-net given.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Delayed medicine hypersensitivity

A T-cell-mediated response commonly begins four to fourteen days after a medicine is started, with earlier recurrence possible after previous exposure.

Frequent culprit groups

Beta-lactam antibiotics, sulfonamides, anticonvulsants and several other medicines are common associations, although infection and polypharmacy complicate attribution.

Viral immune interaction

Acute viral illness can cause a similar exanthem or alter immune response to a concurrent antibiotic, so temporal association alone does not prove allergy.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Drug-specific T-cell activation
Medicine-derived antigens or pharmacological interaction activate lymphocytes that home to skin and release cytokines around superficial dermal vessels.
2
Symmetrical exanthem spread
Inflammation begins predominantly on trunk and proximal limbs, then becomes bilateral and confluent while ordinary epidermal integrity remains preserved.
3
Resolution after withdrawal
When the causal exposure ends, immune recruitment subsides over days and fine desquamation may follow without the full-thickness necrosis of TEN.
4
Pigmentary aftermath
Inflammation can leave prolonged darker or lighter colour, particularly in deeply pigmented skin, despite resolution of active erythema and itch.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Symmetrical trunk exanthem

Small macules and papules start on trunk and proximal limbs, spread bilaterally and may merge while skin remains intact.

Pigmentation-aware inflammation

Active lesions may be red, purple, grey or brown and leave darker macules; palpation and symptom evolution improve detection.

Mucosal preservation

Absence of oral, ocular and genital erosions supports an uncomplicated eruption but requires deliberate examination rather than assumption.

Severe-reaction departureRed flag

Facial oedema, high fever, skin pain, mucosal injury, blistering, detachment, pustules or purpura mandates urgent reassessment.

Organ warningRed flag

Lymphadenopathy, jaundice, breathlessness, reduced urine output or abnormal liver and renal tests suggests systemic drug hypersensitivity.

Red flags requiring action

Skin pain, dusky or targetoid lesions, blisters, detachment, mucosal ulceration, facial oedema, fever, lymphadenopathy, pustules, eosinophilia or liver and kidney abnormalities require urgent escalation.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Complete medicine timelineFirst step
Why
Identify plausible culprit exposures and competing infection.
Interpretation and limitations
Include non-prescription, intermittent, perioperative and recently stopped products; an electronic current list alone misses important latency.
02
Full skin and mucosal examination
Why
Separate uncomplicated exanthem from DRESS, AGEP and epidermal necrolysis.
Interpretation and limitations
Record tenderness, dusky colour, pustules, blisters, detachment and involved mucosal sites; repeat examination if evolution continues.
03
FBC with differential, liver and renal profile
Why
Detect eosinophilia, cytopenia and internal-organ injury when systemic features exist.
Interpretation and limitations
Normal early tests do not guarantee a benign trajectory; trends and symptoms determine whether serial testing is required.
04
Infection-directed tests
Why
Assess a viral or bacterial mimic when history and physiology indicate.
Interpretation and limitations
Avoid broad low-yield screens; infection can coexist with drug hypersensitivity and may make the original medicine essential until alternatives are arranged.
05
Skin biopsy for atypical or severe disease
Why
Support classification when morphology overlaps serious reactions.
Interpretation and limitations
Histology may distinguish patterns but rarely names the culprit; clinicopathological timing remains essential.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Viral exanthem

Systemic viral symptoms, exposure history and absence of a convincing medicine latency can mimic an uncomplicated maculopapular drug eruption.

DRESS syndrome

Longer latency, prominent facial oedema, fever, lymphadenopathy, eosinophilia and internal-organ injury distinguish this potentially prolonged syndrome.

Early SJS or TEN

Skin pain, dusky atypical targets, blistering and mucosal erosion indicate epidermal necrosis rather than a benign morbilliform course.

AGEP

Abrupt fever with numerous small non-follicular pustules and neutrophilia suggests acute generalised exanthematous pustulosis rather than an uncomplicated exanthem.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Typical and systemically wellWithdraw safely and treat symptomsFirst stepThe eruption is symmetrical and itchy, mucosa is normal, skin is not painful and no organ or physiological abnormality exists.

1Review the medicine timeline, stop the most plausible non-essential culprit after arranging any necessary treatment substitute and record uncertainty.
2Use emollient, a site-appropriate topical corticosteroid and a non-sedating antihistamine when itch is prominent, avoiding unnecessary systemic steroids.
3Review within a defined interval and instruct the patient to seek urgent help for fever, facial swelling, mucosal pain, blisters or systemic symptoms.

02Any severity featureAdmit and classify the reactionSkin pain, mucosal erosion, blistering, pustules, facial oedema, high fever or organ symptoms accompany the exanthem.

1Stop non-essential suspected medicines, perform ABC assessment and obtain same-day dermatology and acute-medical input.
2Check FBC, liver, renal and other organ tests guided by symptoms, photograph with consent and consider biopsy from an informative lesion.
3Manage as possible DRESS, SJS, TEN or AGEP until trajectory, histology and serial organ assessment support a safer diagnosis.

03After resolutionImprove the allergy recordThe rash is settling and future prescribing decisions need a usable account of likelihood and severity.

1Document generic and brand names, route, dates, latency, morphology, mucosal and organ findings, treatment and degree of causal certainty.
2Explain which medicine to avoid pending review and distinguish that drug from unrelated agents rather than assigning a blanket class allergy.
3Refer for specialist drug-allergy assessment when the culprit is essential, the history is severe or several simultaneous medicines remain plausible.

Key medicines and prescribing safety2 treatments · regimens, roles and cautions

A potent topical corticosteroid for symptomatic inflammation in a limited uncomplicated drug exanthem after severe reaction has been excluded.

Betamethasone valerate 0.1% cream

Apply a thin film to affected trunk or limb skin once or twice daily for up to four weeks, using the shortest course and amount that controls inflammation.

Avoid face, flexures, genital skin, infection, large areas and occlusion unless specifically directed; review atrophy, systemic absorption risk and diagnostic masking.

Can reduce accompanying itch but does not treat organ involvement or prevent progression of a severe cutaneous adverse reaction.

Cetirizine 10 mg tablets

Adults and adolescents aged 12 years and over take 10 mg orally once daily, with renal dose reduction according to the current SmPC.

Check drowsiness, driving, alcohol, renal function, pregnancy and breastfeeding; symptomatic improvement must not override new fever, skin pain, mucosal disease or blistering.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Progression to severe reaction

An eruption initially described as morbilliform may evolve with systemic or epidermal warning signs and must be re-examined when symptoms change.

Incorrect allergy label

Recording a whole drug class as life-threatening allergy without phenotype and timing can deny effective treatment and promote broader antimicrobial use.

Repeat exposure

Failure to document the likely culprit and uncertainty can lead to re-administration before specialist review and a faster or more severe recurrence.

Persistent pigment change

Post-inflammatory hyperpigmentation or hypopigmentation can remain visible for months and should not be mistaken for ongoing drug activity.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

For an outpatient morbilliform eruption, arrange early review until no new lesions or systemic symptoms emerge and the medicine plan is stable.
Repeat FBC, liver and renal tests when initial systemic features, eosinophilia or organ abnormalities make delayed evolution plausible.
At recovery, review the allergy entry with the patient and provide written details precise enough for future prescribers.
At every review of Morbilliform drug eruption, record lesion evolution, new mucosal or systemic features, medicine changes, treatment adherence and adverse effects.
Give a named route for urgent reassessment if breathing, circulation, fever, skin pain, blistering, facial swelling, reduced urine output or other organ symptoms develop during Morbilliform drug eruption.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

The medicine list needs dates

A named drug without start and stop timing cannot be matched meaningfully to the eruption’s immune latency.

Purple can represent active erythema

In deeply pigmented skin, violaceous or grey-brown change with warmth and itch may signal ongoing inflammation.

Mucosa separates pathways

A routine exanthem spares mucosa; erosions shift the working diagnosis toward epidermal necrolysis or another severe reaction.

Essential drugs need coordination

Stopping antimicrobial or anticonvulsant treatment without a safe substitute can harm, so involve the responsible specialty promptly.

Photographs preserve evolution

Consented images can show whether lesions became dusky, pustular or blistered after an initially bland presentation.

11Common pitfallsFrequent interpretation and management errors.

01
Calling an eruption simple without examining oral, ocular and genital mucosa with consent.
02
Listing all concurrent medicines as anaphylaxis despite a delayed non-urticarial phenotype.
03
Continuing a plausible non-essential culprit because laboratory tests are initially normal.
04
Using oral corticosteroids to suppress an evolving severe reaction without diagnosis or monitoring.
05
Ignoring post-inflammatory hyperpigmentation and telling the patient that visible residual colour means ongoing allergy.